Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
View in:
PubMed
subject areas
Antineoplastic Agents
Biosimilar Pharmaceuticals
Cost Savings
Cost-Benefit Analysis
Drug Costs
Drugs, Generic
Economic Competition
Health Expenditures
Health Services Needs and Demand
Humans
United States
authors with profiles
Charles Lee Bennett